Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DCBY02 / DynamiCure Biotech
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors	Terminated	1	5	US	DCBY02	DynamiCure Biotechnology	Advanced or Metastatic Solid Tumors	02/24	02/24
DCSZ11 / DynamiCure Biotech
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors	Recruiting	1	257	US, RoW	DCSZ11, Pembrolizumab	DynamiCure Biotechnology	Advanced or Metastatic Solid Tumors	12/25	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DCBY02 / DynamiCure Biotech
NCT05496595: DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors	Terminated	1	5	US	DCBY02	DynamiCure Biotechnology	Advanced or Metastatic Solid Tumors	02/24	02/24
DCSZ11 / DynamiCure Biotech
NCT05785754: DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors	Recruiting	1	257	US, RoW	DCSZ11, Pembrolizumab	DynamiCure Biotechnology	Advanced or Metastatic Solid Tumors	12/25	12/26